High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disorders.

[1]  J. Luong,et al.  Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: An emerging threat. , 2019, Biotechnology advances.

[2]  G. Avery.  Biotin interference in immunoassay: a review for the laboratory scientist , 2019, Annals of clinical biochemistry.

[3]  L. de Koning,et al.  Strategies for mitigating risk posed by biotin interference on clinical immunoassays. , 2019, Clinical biochemistry.

[4]  T. Bednarczuk,et al.  The effect of biotin interference on the results of blood hormone assays. , 2019, Endokrynologia Polska.

[5]  H. Luu,et al.  Further assessment of the prevalence of biotin supplementation and its impact on risk. , 2019, Clinical Biochemistry.

[6]  E. Wagar,et al.  Comprehensive assessment of biotin interference in immunoassays. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[7]  A. Mattman,et al.  Approach to the interpretation of unexpected laboratory results arising in the care of patients with inborn errors of metabolism (IEM) , 2018, Reviews in Endocrine and Metabolic Disorders.

[8]  S. Lipner.  Rethinking biotin therapy for hair, nail, and skin disorders. , 2018, Journal of the American Academy of Dermatology.

[9]  S. Lipner,et al.  Biotin for the treatment of nail disease: what is the evidence? , 2018, The Journal of dermatological treatment.

[10]  K. Sikaris,et al.  Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin–biotin immunoassays , 2018, Annals of clinical biochemistry.

[11]  K. Sikaris,et al.  Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays , 2018, Annals of clinical biochemistry.

[12]  M. Duchowny,et al.  Biotin and Acetazolamide for Treatment of an Unusual Child With Autism Plus Lack of Nail and Hair Growth. , 2017, Pediatric neurology.

[13]  P. Y. Zhang,et al.  [Biotin-thiamine-responsive basal ganglia disease]. , 2018, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[14]  M. Emanuele,et al.  Biotin Interference in Clinical Immunoassays: A Cause for Concern. , 2017, Archives of pathology & laboratory medicine.

[15]  A. Imbard,et al.  Adult-onset biotinidase deficiency: two individuals with severe, but reversible optic neuropathy , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  N. Frey,et al.  Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference , 2017 .

[17]  P. Chanson,et al.  High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference , 2017, Clinical chemistry and laboratory medicine.

[18]  Vinita Singh,et al.  BIOTIN INTERFERENCE WITH ROUTINE CLINICAL IMMUNOASSAYS: UNDERSTAND THE CAUSES AND MITIGATE THE RISKS. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[19]  L. Lam,et al.  A simple method to detect biotin interference on immunoassays , 2017, Clinical chemistry and laboratory medicine.

[20]  L. Castelo-Soccio,et al.  A Review of the Use of Biotin for Hair Loss , 2017, Skin Appendage Disorders.

[21]  B. Wolf.  Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening , 2016, Genetics in Medicine.

[22]  G. Birnbaum,et al.  High dose biotin as treatment for progressive multiple sclerosis. , 2016, Multiple sclerosis and related disorders.

[23]  B. Wolf,et al.  Irreversibility of Symptoms with Biotin Therapy in an Adult with Profound Biotinidase Deficiency. , 2017, JIMD reports.

[24]  H. Said,et al.  Mutations in SLC5A6 associated with brain, immune, bone, and intestinal dysfunction in a young child , 2017, Human Genetics.

[25]  M. Clanet,et al.  MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study , 2016, Multiple sclerosis.

[26]  F. Distelmaier,et al.  Biotin Treatment Mimicking Graves' Disease. , 2016, The New England journal of medicine.

[27]  P. Laurberg,et al.  Biochemical Hyperthyroidism in a Newborn Baby Caused by Assay Interaction from Biotin Intake , 2016, European Thyroid Journal.

[28]  D. Mock,et al.  Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis , 2016, Expert opinion on drug metabolism & toxicology.

[29]  R. Sulaiman.  Biotin treatment causing erroneous immunoassay results: A word of caution for clinicians. , 2016, Drug discoveries & therapeutics.

[30]  M. Alfadhel,et al.  Treatment of biotin-responsive basal ganglia disease: Open comparative study between the combination of biotin plus thiamine versus thiamine alone. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[31]  K. Pindolia,et al.  Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood , 2015, Multiple sclerosis.

[32]  B. Wolf.  Clinical issues and frequent questions about biotinidase deficiency. , 2010, Molecular genetics and metabolism.

[33]  S. Sobki,et al.  Interference by Biotin Therapy on Measurement of TSH and FT4 by Enzymeimmunoassay on Boehringer Mannheim ES700 Analyser , 1996, Annals of clinical biochemistry.

[34]  B. Wolf,et al.  Biotinidase Deficiency a , 1985, Advances in pediatrics.

[35]  B. Wolf,et al.  Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[36]  L. Surh,et al.  Evidence for a defect of holocarboxylase synthetase activity in cultured lymphoblasts from a patient with biotin-responsive multiple carboxylase deficiency. , 1982, American journal of human genetics.

[37]  W. Nyhan,et al.  Mutant holocarboxylase synthetase: evidence for the enzyme defect in early infantile biotin-responsive multiple carboxylase deficiency. , 1981, The Journal of clinical investigation.

[38]  D. Crowell,et al.  Multiple carboxylase deficiency: clinical and biochemical improvement following neonatal biotin treatment. , 1981, Pediatrics.